Emmaus Life Sciences, Inc. (EMMA)
OTCMKTS
· Delayed Price · Currency is USD
0.0189
-0.0011 (-5.50%)
Mar 25, 2025, 10:35 AM EST
Emmaus Life Sciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 20.43 | 29.6 | 18.39 | 20.61 | 23.17 | 22.75 | Upgrade
|
| Revenue Growth (YoY) | -28.22% | 60.94% | -10.77% | -11.04% | 1.82% | 38.23% | Upgrade
|
| Cost of Revenue | 1.08 | 1.34 | 2.59 | 3.31 | 2.25 | 1.09 | Upgrade
|
| Gross Profit | 19.35 | 28.26 | 15.8 | 17.3 | 20.92 | 21.66 | Upgrade
|
| Selling, General & Admin | 18.64 | 23.53 | 20.66 | 19.32 | 18.54 | 21.59 | Upgrade
|
| Research & Development | 0.69 | 1.19 | 1.73 | 4.11 | 2.41 | 2.18 | Upgrade
|
| Operating Expenses | 19.33 | 24.72 | 22.39 | 23.43 | 20.95 | 23.77 | Upgrade
|
| Operating Income | 0.02 | 3.54 | -6.59 | -6.13 | -0.03 | -2.11 | Upgrade
|
| Interest Expense | -6.39 | -7.38 | -5.01 | -3.1 | -5.99 | -27.63 | Upgrade
|
| Interest & Investment Income | 0.59 | 0.68 | 0.68 | 0.76 | 0.3 | 0.23 | Upgrade
|
| Earnings From Equity Investments | -0.37 | -1.71 | -1.91 | -2.73 | -2.06 | -0.41 | Upgrade
|
| Currency Exchange Gain (Loss) | 1.45 | -1.77 | -2.66 | -2.02 | 1.5 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 0.8 | 3.97 | 5.56 | -2.34 | 0.5 | 3.68 | Upgrade
|
| EBT Excluding Unusual Items | -3.9 | -2.67 | -9.93 | -15.56 | -5.77 | -26.24 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | - | - | -2.71 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.54 | -0.3 | -0.13 | - | 7.67 | -21.95 | Upgrade
|
| Other Unusual Items | 0.86 | -0.82 | -0.5 | -0.37 | -0.93 | -3.78 | Upgrade
|
| Pretax Income | -3.59 | -3.79 | -10.57 | -15.92 | 0.97 | -54.68 | Upgrade
|
| Income Tax Expense | -0.09 | -0.06 | 0.06 | 0.03 | -0.38 | 0.16 | Upgrade
|
| Net Income | -3.5 | -3.73 | -10.63 | -15.95 | 1.35 | -54.84 | Upgrade
|
| Net Income to Common | -3.5 | -3.73 | -10.63 | -15.95 | 1.35 | -54.84 | Upgrade
|
| Shares Outstanding (Basic) | 61 | 53 | 49 | 49 | 49 | 42 | Upgrade
|
| Shares Outstanding (Diluted) | 61 | 53 | 49 | 49 | 49 | 42 | Upgrade
|
| Shares Change (YoY) | 18.10% | 7.41% | 0.38% | 0.73% | 15.71% | 14.66% | Upgrade
|
| EPS (Basic) | -0.06 | -0.07 | -0.21 | -0.32 | 0.03 | -1.30 | Upgrade
|
| EPS (Diluted) | -0.06 | -0.07 | -0.21 | -0.32 | 0.03 | -1.30 | Upgrade
|
| Free Cash Flow | -1.61 | -1.52 | -5.1 | -1.33 | -2.47 | -4.58 | Upgrade
|
| Free Cash Flow Per Share | -0.03 | -0.03 | -0.10 | -0.03 | -0.05 | -0.11 | Upgrade
|
| Gross Margin | 94.70% | 95.47% | 85.93% | 83.93% | 90.30% | 95.19% | Upgrade
|
| Operating Margin | 0.09% | 11.96% | -35.81% | -29.73% | -0.14% | -9.28% | Upgrade
|
| Profit Margin | -17.11% | -12.61% | -57.78% | -77.37% | 5.85% | -241.04% | Upgrade
|
| Free Cash Flow Margin | -7.86% | -5.14% | -27.73% | -6.44% | -10.64% | -20.14% | Upgrade
|
| EBITDA | 0.04 | 3.57 | -6.53 | -6.07 | 0.03 | -2.04 | Upgrade
|
| EBITDA Margin | 0.20% | 12.07% | -35.52% | -29.45% | 0.12% | -8.96% | Upgrade
|
| D&A For EBITDA | 0.02 | 0.03 | 0.05 | 0.06 | 0.06 | 0.07 | Upgrade
|
| EBIT | 0.02 | 3.54 | -6.59 | -6.13 | -0.03 | -2.11 | Upgrade
|
| EBIT Margin | 0.09% | 11.96% | -35.81% | -29.73% | -0.14% | -9.28% | Upgrade
|
Updated Nov 19, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.